Codexis announces that it has dosed the first subjects in a first-in-human Phase 1a dose-escalation trial with CDX-6114, its orally administered enzyme therapeutic being developed for the management of phenylketonuria. The initiation of the trial triggers a $4M milestone payment to Codexis from Nestle Health Science under their strategic collaboration announced in October 2017.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.